KRAS and colorectal cancer: Yu and coworkers reported that driver mutations in colorectal cancer (KRAS and TP53) resulted in overexpression of TF via MEK/mitogen-activated protein (MAPK) and phosphatidylinositol 3’kinase (PI3K) [30].